About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Obviousness-type Double Patenting after Amgen v. F. Hoffmann-La Roche | Main | In re '318 Patent Infringement Litigation (Fed. Cir. 2009) »

September 28, 2009

Comments

A welcome outcome, but hardly surprising, given that Judges Newman and Rader were on the panel. At least their positions have been consistent over the years. What do you make of Judge Prost's position here versus her position in Aventis v Amphastar?

Kevin,

Nice article. But my question remains: what is the difference between Compound 24028 and Schmutz X? From the formulas in the case, these look to be structurally identical.

Dear Dan:

I think the difference illustrates the problem - inequitable conduct cases will always depend heavily on the facts and the "smell test" - does it look like something underhanded was done? And, of course, the panel - I suspect Judges Newman and Rader can be very persuasive that finding inequitable conduct should be rare, and particularly rare in cases where the district court doesn't think it exists, and even more rare when the district court grants summary judgment of no inequitable conduct.

But I agree it isn't a surprise. Thanks for the comment.

Dear EG:

There must have been a typo in the case, since you are correct, they are identical.

Thanks for noticing.

Kevin,

Thanks for confirming that what I saw isn't a figment of my imagination. If it is a typo, then I wonder which of the formulas for Compound 24028 and Schmutz X is correct.

I've got any even scarier thought: what if the formulas shown in the case are correct, i.e., Compound 24028 and Schmutz are the same. If they are correct/the same, then Teva/Sandoz has a real beef about why AstraZeneca represented that they had no data on Schmutz X.

We'll have to wait and see if the Federal Circuit issues a correction notice.

The point isn't that they didn't have data on 24028. The point was that Schmutz B was more similar to quetiapine than Schmutz X and that the existing compounds were unpredictable.

That said, maybe they should have presented all compounds and argued that the effects of "simple" substitutions were not predictable.

The comments to this entry are closed.

September 2020

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30